CLINICAL RESEARCH
The Cholesterol Deniers
For decades, a tiny encampment of researchers has held that statin treatment
is a hoax. In a time when contrarian views roar to life on social media, how
can medicine keep minority opinions from doing irreparable harm? by Anita Slomski //
Art by Travis Rathbone/Trunk Archive
CARDIOLOGIST STEVEN NISSEN, chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic, delights in the reputation he has earned among his critics. One prized possession is a photograph digitally doctored to show him wearing a tinfoil dunce cap, with the headline, “Steven Nissen goes full quack.” The image appeared on the home page of Natural News, a website that promotes fringe theories about vaccines and other practices of conventional medicine. “Those guys call me the statinator,” Nissen says, a testament to his passionate advocacy of statin drugs a tool to prevent heart at
To embed, copy and paste the code into your website or blog:
This article explores the effect of the pandemic on patent trials. Early in the COVID-19 pandemic, rapidly shifting conditions, state and federal guidance, and many unknowns forced federal district courts to adapt their procedures. Courts faced the task of balancing the safety all involved in the case, including court staff, witnesses and lawyers, with concerns over fairness and access to justice.
COVID-19 Procedures by Jurisdiction
District courts with significant patent dockets, such as the U.S. District Courts for the District of Delaware, Northern District of California, Eastern District of Texas and Western District of Texas, all issued COVID-19 governing procedures that followed three basic steps.
Min
Amber Freed, a mother of boy-and-girl twins, has high hopes and aspirations for her son, Maxwell, who was diagnosed with an incredibly rare, unnamed debilitating disease, SLC6A1. The disease is progressive and neurodevelopmental. It causes speech apraxia, intellectual disability, and progresses into a debilitating form of epilepsy.
When the diagnosis was first given to Freed, she immediately sought answers but doctors had devastating news: Not only was there no cure for Maxwell’s disease, there were no existing drugs or therapies to help with the symptoms.
After tracking down a well-respected scientist, Dr. Steven Gray of the University of Texas Southwestern Medical Center, Freed flew to Washington, D.C. for a conference she knew he was attending and the two sat down for a four-hour long dinner. During the dinner, Freed learned that Maxwell was a good candidate for gene replacement therapy and thus, discussed a treatment plan.
RepliCel Life Sciences, Inc.: RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life Sciences Inc. (OTCPINK:REPCF) (TSXV:RP) (FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that Professor Akimichi Morita, one of Japan s leading dermatology research clinicians, has agreed to be RepliCel s clinical advisor for the development and commercialization of its skin rejuvenation product (RCS-01) in Japan.
The Company, working with industry leaders, CJ Partners, and clinical research organization, Accerise, is currently preparing to support the next-phase clinical research study of its skin rejuvenation cell therapy, RCS-01, in Japan under the Act for Safety of Regenerative Medicine (ASRM) that, upon successfully meeting its endpoints, could lead to a commercial launch of the product in Japan.
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.